Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

17.5%

285 terminated/withdrawn out of 1624 trials

Success Rate

78.8%

-7.7% vs industry average

Late-Stage Pipeline

13%

207 trials in Phase 3/4

Results Transparency

68%

719 of 1059 completed trials have results

Key Signals

110 recruiting719 with results218 terminated67 withdrawn

Enrollment Performance

Analytics

Phase 2
714(47.6%)
Phase 1
510(34.0%)
Phase 3
127(8.5%)
Phase 4
80(5.3%)
N/A
47(3.1%)
Early Phase 1
22(1.5%)
1500Total
Phase 2(714)
Phase 1(510)
Phase 3(127)
Phase 4(80)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (1624)

Showing 20 of 1624 trials
NCT03526432Phase 2Active Not Recruiting

Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer

Role: collaborator

NCT07566364Phase 2Recruiting

Phase 2 Study Of Mosunetuzumab In Patients With Chronic Lymphocytic Leukemia With Positive MRD

Role: collaborator

NCT00505245Recruiting

New Assessment System in Measuring Symptom Distress in Cancer Patients

Role: collaborator

NCT07609719Phase 4Recruiting

A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy

Role: lead

NCT06031441Phase 1Active Not Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Role: lead

NCT06619587Phase 1Recruiting

A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors

Role: lead

NCT07059494Phase 4Recruiting

Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant

Role: collaborator

NCT06979336Phase 2Recruiting

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

Role: lead

NCT06252675Phase 2Recruiting

Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

Role: collaborator

NCT03602820Active Not Recruiting

Long-term Follow-up Study in Subjects Who Received Voretigene Neparvovec-rzyl (AAV2-hRPE65v2)

Role: lead

NCT02252887Phase 2Completed

Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy

Role: collaborator

NCT05034627Phase 1Completed

Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

Role: collaborator

NCT00076310Phase 2Completed

OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer

Role: collaborator

NCT06847542Phase 3Recruiting

A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD

Role: collaborator

NCT06765317Phase 2Recruiting

A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma

Role: collaborator

NCT04409639Phase 2Active Not Recruiting

Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations

Role: collaborator

NCT04893109Phase 2Recruiting

ATEMPT 2.0: Adjuvant T-DM1 vs TH

Role: collaborator

NCT07342114Phase 1Recruiting

A Dose-Escalation Study of RO7875913 in Healthy Participants

Role: lead

NCT07558915Phase 1Recruiting

A Study to Evaluate RO7851624 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Role: lead

NCT07541079Phase 3Recruiting

A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)

Role: lead